Table 4 Distribution of prevalence of malaria infection by clinical and laboratory factors
Characteristics | Number positive (%), n = 26 | Number negative (%), n = 216 | p value |
|---|---|---|---|
No | 6 (26.1) | 17 (73.9) | 0.012 |
Yes | 20 (9.1) | 199 (90.8) | Â |
WHO HIV clinical stage | |||
 Stage 1 | 7 (8.8) | 93 (91.2) | 0.153 |
 Stage 2 | 7 (8.0) | 81 (92.1) |  |
 Stage 3 | 6 (17.7) | 28 (82.4) |  |
 Stage 4 | 4 (22.2) | 14 (77.8) |  |
Duration on ART | |||
 ≤ 6 months | 2 (10.5) | 17 (89.5) | 0.975 |
 > 6 months | 24 (10.8) | 199 (89.2) |  |
Types of ART regimen | |||
 First-line ART | 25 (11.1) | 201 (88.9) | 0.774 |
 Second-line ART | 1 (7.7) | 12 (92.3) |  |
 Third line ART | – | 3 (100) |  |
Adherence on ART | |||
 Good | 19 (8.6) | 203 (91.4) | 0.001 |
 Poor | 7 (35.0) | 13 (65.0) |  |
Other comorbidities* | |||
 No | 20 (9.3) | 195 (90.7) | 0.041 |
 Yes | 6 (22.2) | 21 (77.8) |  |
TB status | |||
 No | 21 (9.5) | 201 (90.5) | 0.032 |
 Yes | 5 (25.0) | 15 (75.0) |  |
Viral load | |||
 < 1000 copies/mL | 20 (9.3) | 195 (90.7) | 0.041 |
 ≥ 1000 copies/mL | 6 (22.2) | 21 (77.8) |  |
CD4 count | |||
 ≤ 350 cells/µl | 15 (21.7) | 54 (78.3) |  < 0.001 |
 > 350 cells/µl | 11 (6.4) | 162 (93.6) |  |